- Home
- EICC vs VCEL Comparison
EICC vs VCEL Comparison
Compare EICC & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EICC | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | EICC | VCEL |
|---|---|---|
| Price | $24.97 | $29.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $58.50 |
| AVG Volume (30 Days) | 58.1K | ★ 610.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.55 | 0.32 |
| Revenue | $51,224,692.00 | ★ $276,259,000.00 |
| Revenue This Year | $39.61 | $19.10 |
| Revenue Next Year | $27.28 | $17.95 |
| P/E Ratio | ★ $45.23 | $96.31 |
| Revenue Growth | ★ 68.61 | 16.45 |
| 52 Week Low | $23.75 | $29.24 |
| 52 Week High | $25.84 | $45.97 |
Technical Indicators
Market Signals| Indicator | EICC | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 30.35 |
| Support Level | $24.92 | N/A |
| Resistance Level | $25.19 | $38.48 |
| Average True Range (ATR) | 0.03 | 1.52 |
| MACD | 0.00 | -0.18 |
| Stochastic Oscillator | 43.81 | 9.09 |
Price Performance
Historical ComparisonAbout EICC Eagle Point Income Company Inc. 8.00% Series C Term Preferred Stock due 2029
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.